Reunion Neuroscience to Present Full Data from RECONNECT Phase 2 Clinical Trial at Upcoming ASCP and APA Annual Meetings

Reunion Neuroscience to Present Full RECONNECT Phase 2 Data for Luvesilocin in PPD

Reunion Neuroscience announced it will present full results from its RECONNECT Phase 2 trial evaluating luvesilocin in adult female patients with moderate-to-severe postpartum depression (PPD) at the American Society of Clinical Psychopharmacology (ASCP) and American Psychiatric Association (APA) Annual Meetings. The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful reduction in depression (MADRS total score) by Day 7, with effects maintained through 28 days. Significant improvements were also observed in key secondary endpoints. Based on these positive data, Reunion Neuroscience has aligned with the U.S. FDA on a registrational path and plans to initiate a pivotal Phase 3 trial in 2026, which, if successful, could support potential registration.

• The RECONNECT Phase 2 trial successfully met its primary endpoint, demonstrating a statistically significant and clinically meaningful reduction in depression, as measured by the MADRS total score, by Day 7 in adult female patients with moderate-to-severe postpartum depression. Clinically meaningful reductions were observed as early as the first day following administration of luvesilocin 30mg and were sustained throughout the 28-day follow-up period.
• Beyond the primary endpoint, the trial also showed substantial and clinically meaningful improvements in key secondary endpoints. These included enhanced MADRS response and remission rates, alongside other measures related to PPD symptoms. These comprehensive positive results underscore luvesilocin's potential to offer a rapid and sustained therapeutic benefit for patients suffering from postpartum depression.
• Following the positive Phase 2 data, Reunion Neuroscience has successfully aligned with the U.S. Food and Drug Administration (FDA) on a clear registrational path for luvesilocin in PPD. The company anticipates initiating a pivotal Phase 3 trial in 2026. If this single Phase 3 trial proves successful, its results are expected to complete the data package required to support the potential registration of luvesilocin for PPD.

RECONNECT Phase 2: Luvesilocin's Efficacy and Safety in PPD

Recent studies demonstrate evolving therapeutic approaches for postpartum depression, ranging from novel neurosteroid modulators to psychotherapeutic interventions. These investigations provide critical insights into both pharmacological and non-pharmacological treatment options with varying levels of evidence quality.

• Oral zuranolone showed moderate-certainty evidence for efficacy with depression response rates of RR 1.26 (95% CI 1.03-1.55) and remission rates of RR 1.65 (95% CI 1.22-2.22) at 45 days, though it probably increases maternal adverse events (RR 1.24, 95% CI 1.03-1.48) with somnolence as the most frequent adverse event

• Intravenous brexanolone demonstrated limited efficacy with low-certainty evidence suggesting little difference in depression response (RR 1.24, 95% CI 0.74-2.06) or remission (RR 1.18, 95% CI 0.59-2.38) at 30 days, while showing lower treatment acceptability than placebo (RR 2.77, 95% CI 1.22-6.26)

• Prophylactic esketamine significantly reduced PPD incidence from 20.89% to 11.59% (adjusted RR 0.57, 95% CI 0.35-0.94) within 3 months, with early effects at 7 days (4.89% vs 15.19%), though associated with mild central nervous events including dizziness (10.98%), hallucination (10.37%), and dissociation (5.49%)

• Brief Interpersonal Psychotherapy during pregnancy demonstrated sustained benefits through 1-year postpartum with significantly lower MDD rates (4.33% vs 12.93%, OR=3.20, P=0.021) and improved depression scores on both SCL-20 and EPDS measures compared to enhanced usual care

• Infantile anti-colic massage interventions showed greatest maternal functioning improvement (12.31 ± 5.93, p<0.001) compared to kangaroo care and control groups, with smaller decreases in postpartum anxiety and depression scores in the control group (5.29 ± 9.51 vs 1.39 ± 1.28)

PPD Progress: The RECONNECT Name's Double-Edged Sword

Reunion Neuroscience's announcement of positive Phase 2 results for luvesilocin in postpartum depression (PPD) represents a promising step forward for patients grappling with this debilitating condition. The reported rapid and sustained reduction in depression scores, coupled with FDA alignment on a registrational path, signals a clear and potentially accelerated development trajectory for this novel therapy. This progress is particularly encouraging given the significant unmet need for effective and timely interventions in PPD.

However, the journey to market for luvesilocin will unfold under a unique spotlight, largely due to its Phase 2 trial sharing the name "RECONNECT." This designation carries a historical context within clinical research, as previous "RECONNECT" trials for bremelanotide in hypoactive sexual desire disorder (HSDD) have been subject to considerable scrutiny. Research on these prior trials highlighted concerns regarding the "small effects" and "questionable outcomes" observed, particularly concerning the validity and clinical meaningfulness of certain efficacy measures.

For Reunion Neuroscience, this means that while the initial Phase 2 data is positive, the upcoming pivotal Phase 3 trial for luvesilocin will likely face heightened examination. The company must ensure its trial design, chosen endpoints, and statistical analyses are exceptionally robust, demonstrating unequivocally both statistical significance and profound clinical meaningfulness. The importance of validated patient-reported outcome measures and clear responder analyses, as emphasized in the bremelanotide literature, will be paramount. Proactive communication will also be crucial to differentiate luvesilocin's profile and data from any historical associations, ensuring stakeholders focus on the merits of this new PPD treatment. Successfully navigating this landscape will be key to establishing luvesilocin as a trusted and impactful therapy for PPD.